Anti-Ricin Protective Monoclonal Antibodies

PDF

Authors
  1. Hu, W-G.
  2. Yin, J.
  3. Chau, D.
  4. Hu, C.C.
  5. Cherwonogrodzky, J.W.
Corporate Authors
Defence R&D Canada - Suffield, Ralston ALTA (CAN)
Abstract
Development of anti-ricin protective monoclonal antibodies (mAbs) started in the early 1980s. Much progress has been made since then. Antibodies represent a great potential to be developed as antidotes against toxins. They can be used either prophylactically to prevent or therapeutically to treat toxin-mediated intoxications in an emergency situation. Unlike many other therapeutic products, antibodies offer unique and high target specificity, and long half-life in serum. There are a dozen of mAbs, which are currently in the discovery stage for medical countermeasures against ricin intoxication. This review summarizes these mAbs, including their anti-ricin mechanism, generation, and efficacies in vivo.
Report Number
DRDC-SUFFIELD-SL-2013-028 — Scientific Letter
Date of publication
08 Feb 2017
Number of Pages
18
DSTKIM No
CA044646
CANDIS No
804970
Format(s):
Electronic Document(PDF)

Permanent link

Document 1 of 1

Date modified: